Obstacles to the Successful Development of an Efficacious T Cell-inducing HIV-1 Vaccine

Overview

Journal J Leukoc Biol

Publisher Oxford University Press

Specialty Allergy & Immunology

Date 2009 Jul 15

PMID 19597003

Citations 10

Authors

Larissa Herkenhoff Haut

Hildegund C J Ertl

Affiliations

Soon will be listed here.

Abstract

An efficacious vaccine to HIV-1 is direly needed to stem the global pandemic. Immunogens that elicit broadly cross-neutralizing antibodies to HIV-1 remain elusive, and thus, most HIV-1 vaccine efforts are focusing on induction of T cells. The notion that T cells can mediate protection against HIV-1 has been called into question by the failure of the STEP trial, which was designed to test this concept by the use of an E1-deleted Ad vaccine carrier. Lack of efficacy of the STEP trial vaccine underscores our limited knowledge about correlates of immune protection against HIV-1 and stresses the need for an enhanced commitment to basic research, including preclinical and clinical vaccine studies. In this review, we discuss known correlates of protection against HIV-1 and different vaccine strategies that have been or are being explored to induce such correlates, focusing on T cell-inducing vaccines and particularly on Ad vectors.

Citing Articles

Regulation of the pyruvate metabolism node by monogene and polygene engineering of HEK-293 cells.

Xie L, Miao J, Li X, Yi X, Chu J RSC Adv. 2022; 9(61):35760-35770.

PMID: 35528064 PMC: 9074685. DOI: 10.1039/c9ra07418j.

Post-Immune Antibodies in HIV-1 Infection in the Context of Vaccine Development: A Variety of Biological Functions and Catalytic Activities.

Timofeeva A, Sedykh S, Nevinsky G Vaccines (Basel). 2022; 10(3).

PMID: 35335016 PMC: 8955465. DOI: 10.3390/vaccines10030384.

An HIV-1 Mini Vaccine Induced Long-lived Cellular and Humoral Immune Responses.

Mahdavi M, Ebtekar M, Hassan Z, Faezi S, Khorram Khorshid H, Taghizadeh M Int J Mol Cell Med. 2016; 4(4):218-26.

PMID: 27014646 PMC: 4769599.

Genetically modified hematopoietic stem cell transplantation for HIV-1-infected patients: can we achieve a cure?.

Younan P, Kowalski J, Kiem H Mol Ther. 2013; 22(2):257-264.

PMID: 24220323 PMC: 3916050. DOI: 10.1038/mt.2013.264.

Preventing spontaneous genetic rearrangements in the transgene cassettes of adenovirus vectors.

Cottingham M, Carroll F, Morris S, Turner A, Vaughan A, Kapulu M Biotechnol Bioeng. 2012; 109(3):719-28.

PMID: 22252512 PMC: 4981243. DOI: 10.1002/bit.24342.

References

Mascola J, Sambor A, Beaudry K, Santra S, Welcher B, Louder M . Neutralizing antibodies elicited by immunization of monkeys with DNA plasmids and recombinant adenoviral vectors expressing human immunodeficiency virus type 1 proteins. J Virol. 2004; 79(2):771-9. PMC: 538538. DOI: 10.1128/JVI.79.2.771-779.2005. View

Rerks-Ngarm S, Brown A, Khamboonruang C, Thongcharoen P, Kunasol P . HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand. AIDS. 2006; 20(11):1471-9. DOI: 10.1097/01.aids.0000237362.26370.f8. View

Catanzaro A, Koup R, Roederer M, Bailer R, Enama M, Moodie Z . Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 candidate vaccine delivered by a replication-defective recombinant adenovirus vector. J Infect Dis. 2006; 194(12):1638-49. PMC: 2428071. DOI: 10.1086/509258. View

Yan J, Hokey D, Morrow M, Corbitt N, Harris K, Harris D . Novel SIVmac DNA vaccines encoding Env, Pol and Gag consensus proteins elicit strong cellular immune responses in cynomolgus macaques. Vaccine. 2009; 27(25-26):3260-6. DOI: 10.1016/j.vaccine.2009.01.065. View

Boyer J, Robinson T, Maciag P, Peng X, Johnson R, Pavlakis G . DNA prime Listeria boost induces a cellular immune response to SIV antigens in the rhesus macaque model that is capable of limited suppression of SIV239 viral replication. Virology. 2005; 333(1):88-101. DOI: 10.1016/j.virol.2004.12.026. View

Guerbois M, Moris A, Combredet C, Najburg V, Ruffie C, Fevrier M . Live attenuated measles vaccine expressing HIV-1 Gag virus like particles covered with gp160DeltaV1V2 is strongly immunogenic. Virology. 2009; 388(1):191-203. DOI: 10.1016/j.virol.2009.02.047. View

Zuckerman A, Hamburger Y, Spira D . Active immunization of rats with a cell-free extract of the erythrocytic parasites of Plasmodium berghei. Exp Parasitol. 1967; 21(1):84-97. DOI: 10.1016/0014-4894(67)90071-9. View

Johnson P, Schnepp B, Connell M, Rohne D, Robinson S, Krivulka G . Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques. J Virol. 2004; 79(2):955-65. PMC: 538580. DOI: 10.1128/JVI.79.2.955-965.2005. View

Sullivan P, Hanson D, Dworkin M, Jones J, Ward J . Effect of influenza vaccination on disease progression among HIV-infected persons. AIDS. 2000; 14(17):2781-5. DOI: 10.1097/00002030-200012010-00018. View

10.

Graham F, Prevec L . Adenovirus-based expression vectors and recombinant vaccines. Biotechnology. 1992; 20:363-90. DOI: 10.1016/b978-0-7506-9265-6.50022-1. View

11.

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

12.

Sleasman J, Goodenow M . 13. HIV-1 infection. J Allergy Clin Immunol. 2003; 111(2 Suppl):S582-92. DOI: 10.1067/mai.2003.91. View

13.

Kawahara M . Recombinant Mycobacterium bovis BCG vector system expressing SIV Gag protein stably and persistently induces antigen-specific humoral immune response concomitant with IFN gamma response, even at three years after immunization. Clin Immunol. 2008; 129(3):492-8. DOI: 10.1016/j.clim.2008.08.019. View

14.

Gahery-Segard H, Pialoux G, Figueiredo S, Igea C, Surenaud M, Gaston J . Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J Virol. 2003; 77(20):11220-31. PMC: 224965. DOI: 10.1128/jvi.77.20.11220-11231.2003. View

15.

Chen Y, Helmus R, McClane B, Hoffman R, Watkins S, Wehrli T . Use of a Clostridium perfringens vector to express high levels of SIV p27 protein for the development of an oral SIV vaccine. Virology. 2004; 329(2):226-33. DOI: 10.1016/j.virol.2004.08.018. View

16.

Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

17.

Tatsis N, Tesema L, Robinson E, Giles-Davis W, McCoy K, Gao G . Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther. 2005; 13(5):421-9. DOI: 10.1038/sj.gt.3302675. View

18.

Liu J, Ewald B, Lynch D, Denholtz M, Abbink P, Lemckert A . Magnitude and phenotype of cellular immune responses elicited by recombinant adenovirus vectors and heterologous prime-boost regimens in rhesus monkeys. J Virol. 2008; 82(10):4844-52. PMC: 2346755. DOI: 10.1128/JVI.02616-07. View

19.

Kawada M, Tsukamoto T, Yamamoto H, Iwamoto N, Kurihara K, Takeda A . Gag-specific cytotoxic T-lymphocyte-based control of primary simian immunodeficiency virus replication in a vaccine trial. J Virol. 2008; 82(20):10199-206. PMC: 2566295. DOI: 10.1128/JVI.01103-08. View

20.

Cleghorn F, Pape J, Schechter M, Bartholomew C, Sanchez J, Jack N . Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. J Acquir Immune Defic Syndr. 2007; 46(2):222-30. DOI: 10.1097/QAI.0b013e318149297d. View